Abstract
Human epidermal keratinocytes (EKs) are metabolically involved in various drug transport mechanisms, as well as in detoxification or activation processes. The overall cell mechanisms of drug metabolization, and more specifically drug processing are reviewed in normal EKs. The overall drug metabolism involves different phases corresponding to the uptake, biotransformation and anti-transport steps. In EKs, both the enzymes and transportassociated proteins are different from those involved in the hepatocyte metabolism. Some cytochrome P450 enzymes and the flavin-containing mono-oxygenases are particularly involved in EKs. Basically, EKs represent key cells likely involved during the initial stage of drug-induced toxic epidermal necrolysis (TEN). Only limited advances have been made so far in this field. Nevertheless, mitigating EKs metabolic disturbances in TEN probably represent a promising specific treatment of the disease.
Keywords: Drug metabolism, toxic epidermal necrolysis, drug disposition, biotransformation, anti-transport mechanism, cytochrome P450, keratinocyte, aromatic anti-epileptics, lamotrigine, pantoprazole
Current Drug Safety
Title:Drug Interactions with Normal and TEN Epidermal Keratinocytes
Volume: 7 Issue: 5
Author(s): Philippe Paquet, Philippe Delvenne and Gerald E. Pierard
Affiliation:
Keywords: Drug metabolism, toxic epidermal necrolysis, drug disposition, biotransformation, anti-transport mechanism, cytochrome P450, keratinocyte, aromatic anti-epileptics, lamotrigine, pantoprazole
Abstract: Human epidermal keratinocytes (EKs) are metabolically involved in various drug transport mechanisms, as well as in detoxification or activation processes. The overall cell mechanisms of drug metabolization, and more specifically drug processing are reviewed in normal EKs. The overall drug metabolism involves different phases corresponding to the uptake, biotransformation and anti-transport steps. In EKs, both the enzymes and transportassociated proteins are different from those involved in the hepatocyte metabolism. Some cytochrome P450 enzymes and the flavin-containing mono-oxygenases are particularly involved in EKs. Basically, EKs represent key cells likely involved during the initial stage of drug-induced toxic epidermal necrolysis (TEN). Only limited advances have been made so far in this field. Nevertheless, mitigating EKs metabolic disturbances in TEN probably represent a promising specific treatment of the disease.
Export Options
About this article
Cite this article as:
Paquet Philippe, Delvenne Philippe and E. Pierard Gerald, Drug Interactions with Normal and TEN Epidermal Keratinocytes, Current Drug Safety 2012; 7(5) . https://dx.doi.org/10.2174/1574886311207050004
DOI https://dx.doi.org/10.2174/1574886311207050004 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Blockade of MUC1 Expression by Glycerol Guaiacolate Inhibits Proliferation of Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Chlorotoxin-Conjugated Nanoparticles for Targeted Imaging and Therapy of Glioma
Current Topics in Medicinal Chemistry Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Anti-Tumor Activity and Underlying Mechanism of Phomoxanthone B in MCF7 Cells
Anti-Cancer Agents in Medicinal Chemistry Gallium-68: A New Trend in PET Radiopharmacy
Current Radiopharmaceuticals Patent Selections:
Recent Patents on Cardiovascular Drug Discovery The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS
Current Pharmaceutical Design Targeting Human Telomerase in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic
Current Gene Therapy A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors
Current Topics in Medicinal Chemistry The Role of 18 kDa Mitochondrial Translocator Protein (TSPO) in Programmed Cell Death, and Effects of Steroids on TSPO Expression
Current Molecular Medicine Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies
Current Pharmaceutical Design Antimicrobial Agents Deriving from Indigenous Plants
Recent Patents on Food, Nutrition & Agriculture